| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.064 | 0.3 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.3 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.3 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |